Notably, recent years, there have been several authoritative studies on VGLUT2, and emerging evidence highlights that the balance of VGLUT2 expression in select DA neuronal populations may be a novel identified risk factor or therapeutic target in the progression of PD or other neurodegenerative diseases. Here, SLC17A6 is linked to Parkinson disease.